Accordingly, PAK1 may promote the occurrence and development of GBM via the abnormal activation of PAK1, which suggests that the development of specific PAK1 inhibitors to reduce p-PAK1 for the treatment of some cancers may be very promising. Here, PAK1 is linked to glioblastoma.